Get access to our best features
Get access to our best features
Published

DEA, HHS finalize rule allowing telehealth drug treatment

  • The Biden administration finalized a rule allowing telehealth providers to prescribe six months of buprenorphine without an in-person visit, as stated by the Drug Enforcement Administration and the Substance Abuse and Mental Health Services Administration.
  • The final rule aims to expand access to opioid use disorder treatments and will take effect 30 days after publication in the Federal Register, according to the announcement by the DEA.
  • The DEA will create a special registration process for providers to prescribe controlled substances via telemedicine, fulfilling a mandate from Congress dating back to 2008, as noted in the new regulations.
  • The rules also impose new requirements to prevent misuse of buprenorphine, including checking state prescription databases, which advocates argue may complicate access to treatment, as expressed by the Alliance for Connected Care.
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)